Search

Your search keyword '"Andrea Freixa"' showing total 2 results
Start Over Author "Andrea Freixa" Journal pediatric allergy and immunology
2 results on '"Andrea Freixa"'

1. <scp>Cost‐effectiveness</scp> of omalizumab for the treatment of severe pediatric allergic asthma—Results of a <scp>real‐life</scp> study in Spain

Author

María Nieto‐Cid, Teresa Garriga‐Baraut, Ana Mª. Plaza‐Martín, Miguel Tortajada‐Girbés, Javier Torres‐Borrego, Jaime Lozano‐Blasco, Laura Moreno‐Galarraga, Mª. del Mar Folqué‐Giménez, Montse Bosque‐García, Mirella Gaboli, Alejandro López‐Neyra, Cristina Rivas‐Juesas, Mª. Araceli Caballero‐Rabasco, Andrea Freixa‐Benavente, Laura Valdesoiro‐Navarrete, Inés de Mir‐Messa, Esther Ballester‐Asensio, María Penín‐Antón, Raquel Romero‐García, Juan Navarro‐Morón, Alfredo Valenzuela‐Soria, Mercedes Sánchez‐Mateos, José Batlles‐Garrido, Verónica Sanz‐Santiago, Álvaro Gimeno‐Díaz de Atauri, Anselmo Andrés‐Martín, Elena Campos‐Alonso, David Gómez‐Pastrana, Elena Vázquez‐Rodríguez, Luz Martínez‐Pardo, Genoveva del Río‐Camacho, Ángel Mazón‐Ramos, and Antonio Nieto‐García

Subjects
Immunology, Pediatrics, Perinatology and Child Health, Immunology and Allergy
Published
2023

2. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

Author

Cristina Rivas Juesas, Montserrat Bosque, Luz Martínez Pardo, Mercedes Sánchez Mateos, Alfredo Valenzuela Soria, Miguel Tortajada, Ángel Mazón Ramos, A.M. Plaza, María Nieto Cid, Genoveva del Río Camacho, José Batlles Garrido, Esther Ballester Asensio, Antonio Nieto Garcia, Raquel Romero, Teresa Garriga-Baraut, Elena Vázquez Rodríguez, María Penín Antón, Laura Valdesoiro Navarrete, María Araceli Caballero-Rabasco, Jaime Lozano, Verónica Sanz Santiago, E. Alonso, Alejandro López Neyra, Carmen Aragón Fernández, M M Folque, Juan Navarro Morón, A. Andrés Martín, Álvaro Gimeno Díaz de Atauri, Javier Torres-Borrego, Laura Moreno-Galarraga, Andrea Freixa, and Mirella Gaboli

Subjects
severe asthma, medicine.medical_specialty, Pediatrics, Immunology, real life, Omalizumab, humanized monoclonal antibodies, adolescents, Antibodies, Monoclonal, Humanized, Anti-asthmatic Agent, 03 medical and health sciences, 0302 clinical medicine, children, Internal medicine, medicine, anti-asthmatic agents, Humans, Immunology and Allergy, Children, adolescents, anti-asthmatic agents, humanized monoclonal antibodies, observational study, omalizumab, real-life, severe asthma, Anti-Asthmatic Agents, 030212 general & internal medicine, Child, Adverse effect, Retrospective Studies, business.industry, asthmatic agents, observational study, anti&#8208, Retrospective cohort study, Asthma, Discontinuation, omalizumab, Treatment Outcome, Pulmonology, 030228 respiratory system, Severe persistent allergic asthma, Pediatrics, Perinatology and Child Health, Cohort, Observational study, business, medicine.drug
Abstract

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results